Information  X 
Enter a valid email address

THROMBOGENICS O (0G99)

Date Time Source Announcement
19 Oct 2018 6:30 am
GNW
Oxurion NV Business Update - Q3 2018
20 Sep 2018 4:40 pm
GNW
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
  6:30 am
GNW
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
17 Sep 2018 4:40 pm
GNW
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
10 Sep 2018 6:30 am
GNW
Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit
06 Sep 2018 4:40 pm
GNW
ThromboGenics Business Update - H1 2018
03 Sep 2018 4:40 pm
GNW
ThromboGenics becomes "Oxurion"
19 Jul 2018 4:40 pm
GNW
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
27 Jun 2018 6:30 am
GNW
ThromboGenics Plans Name Change to "Oxurion"
21 Jun 2018 7:00 am
GNW
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
25 May 2018 6:30 am
GNW
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
23 May 2018 7:00 am
GNW
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
09 May 2018 6:30 am
GNW
ThromboGenics Business Update - Q1 2018
06 Apr 2018 6:30 am
GNW
ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema
04 Apr 2018 6:30 am
GNW
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)
15 Mar 2018 4:40 pm
GNW
ThromboGenics Business Update - FY 2017
08 Dec 2017 6:30 am
GNW
Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate
08 Nov 2017 6:30 am
GNW
ThromboGenics Strengthens Leadership Team - Susan Schneider, MD appointed Chief Medical Officer and Vinciane Vangeersdaele appointed Chief Commercial Officer
20 Oct 2017 6:30 am
GNW
ThromboGenics Business Update - Q3 2017
09 Oct 2017 6:30 am
GNW
ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR
28 Sep 2017 4:35 pm
GNW
ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
27 Sep 2017 11:05 pm
GNW
ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
18 Sep 2017 6:30 am
GNW
ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
07 Sep 2017 4:40 pm
GNW
ThromboGenics Business Update - H1 2017
01 Sep 2017 6:30 am
GNW
ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB
16 Aug 2017 6:30 am
GNW
New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston
10 Jul 2017 6:30 am
GNW
BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement
26 Jun 2015 7:00 am
GNW
Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
21 May 2015 6:30 am
GNW
ThromboGenics Q1 2015 Business Update
23 Apr 2015 6:30 am
GNW
ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO)
14 Apr 2015 6:30 am
GNW
ThromboGenics and VIB launch New Oncology Company
24 Mar 2015 1:15 pm
GNW
OASIS Study Clarification with regard to number of ERM Patients recruited
  6:30 am
GNW
ThromboGenics Announces Positive Topline Results from OASIS Study
16 Mar 2015 6:00 am
GNW
ThromboGenics' JETREA® Gains Approval in Brazil
12 Mar 2015 4:40 pm
GNW
ThromboGenics Full Year 2014 Business Update
05 Mar 2015 2:33 pm
GNW
ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor
02 Mar 2015 4:48 pm
GNW
ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA®
05 Feb 2015 7:00 am
GNW
Thrombogenics Awarded €1.1 million IWT Research Grant
22 Jan 2015 9:00 am
GNW
ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director
07 Jan 2015 1:00 pm
GNW
ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer
 
Headlines
Top categories

18-Jan-2019 10:40 AM

Broker Forecast - Barclays Capital issues a broker note on Synthomer

Barclays Capital today reaffirms its overweight investment rating on Synthomer (LON:SYNT) and cut its price target to 540p (from 600p). Story provide ...

Company finder

a d v e r t i s e m e n t